SOPHiA GENETICS (NASDAQ:SOPH) Hits New 12-Month High - Should You Buy?

Key Points

• SOPHiA GENETICS shares reached a new 52-week high of $8.01, well above their 50-day and 200-day moving averages. Analysts’ consensus rating is “Hold,” with an average price target of $10.00, though individual targets range from $9 to $14.
• The company exceeded quarterly revenue expectations, reporting $23.31 million versus $21.72 million expected, but missed on earnings with an EPS loss of $0.26 versus the projected $0.21 loss. SOPHiA remains deeply unprofitable, with a negative net margin of 93.86%.
• Insiders sold 318,592 shares worth approximately $1.95 million during the last quarter, primarily through pre-arranged trading plans, while institutional investors own 31.59% of the stock.

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) hit a new 52-week high on Wednesday . The stock traded as high as $8.01 and last traded at $7.9950, with a volume of 198496 shares trading hands. The stock had previously closed at $7.62.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SOPH. HC Wainwright boosted their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Zacks Research raised SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. BTIG Research boosted their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $10.00.

SOPHiA GENETICS Stock Performance

The company has a market capitalization of $663.91 million, a price-to-earnings ratio of -6.88 and a beta of 0.96. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The company's fifty day simple moving average is $5.98 and its two-hundred day simple moving average is $5.26.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. Equities research analysts predict that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Insider Transactions at SOPHiA GENETICS

In other news, CEO Ross Muken sold 9,838 shares of the business's stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $5.22, for a total value of $51,354.36. Following the completion of the sale, the chief executive officer directly owned 670,651 shares in the company, valued at approximately $3,500,798.22. The trade was a 1.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Zhenyu Xu sold 17,000 shares of the firm's stock in a transaction on Friday, August 7th. The stock was sold at an average price of $7.29, for a total value of $123,930.00. Following the transaction, the insider owned 590,887 shares in the company, valued at $4,307,566.23. This trade represents a 2.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 318,592 shares of company stock worth $1,952,315. 4.88% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On SOPHiA GENETICS

Institutional investors have recently modified their holdings of the business. Silverberg Bernstein Capital Management LLC lifted its position in SOPHiA GENETICS by 8.7% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company's stock valued at $257,000 after purchasing an additional 4,155 shares during the last quarter. Dimensional Fund Advisors LP grew its position in SOPHiA GENETICS by 24.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company's stock worth $148,000 after purchasing an additional 6,205 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock valued at $6,976,000 after purchasing an additional 9,800 shares during the period. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS in the first quarter valued at approximately $50,000. Finally, Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS during the third quarter valued at approximately $49,000. Institutional investors own 31.59% of the company's stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source